1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1396104147

JUN ROSE ABELLA F.N.P.
Prescription History 1396104147
Nurse Practitioner - Family in New York, NY


Quality Rating: 84.47 out of 100 score

NPI Status: Active since February 22, 2016

Contact Information

40 WALL STREET
NEW YORK, NY
ZIP 10005
Phone: (888) 535-6963

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JUN ROSE ABELLA F.N.P., an active Family specialist practicing in New York, NY. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 299 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 82 claims alone.

Medication Index

Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 840
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills46.7
Peer Average Days Supply1,392
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $97,283.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,474.41

State Avg Cost Per Claim

$3,990.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 82
30-Day Fills 157.9
Days Supply 4,725
NY State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills142.7
Peer Average Days Supply4,244
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.1% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,390.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.96

State Avg Cost Per Claim

$28.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Cabometyx

Generic Formulation: Cabozantinib S-MalateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NY State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply666
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $264,174.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$22,014.58

State Avg Cost Per Claim

$22,655.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat various types of cancer (including kidney, thyroid, liver cancer). Cabozantinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 738
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply434
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.16

State Avg Cost Per Claim

$16.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Exemestane

Generic Formulation: ExemestaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 25.0
Days Supply 750
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills65.1
Peer Average Days Supply1,939
Conservative Utilization

This provider writes prescriptions for this formulation 46.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,218.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$130.51

State Avg Cost Per Claim

$280.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Ibrance

Generic Formulation: PalbociclibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 616
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.6
Peer Average Days Supply768
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $338,487.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,385.79

State Avg Cost Per Claim

$14,520.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imbruvica

Generic Formulation: IbrutinibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply908
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $170,877.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,534.32

State Avg Cost Per Claim

$14,730.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 78
30-Day Fills 216.7
Days Supply 6,502
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills106.0
Peer Average Days Supply3,158
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 62.5% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,306.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.57

State Avg Cost Per Claim

$29.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply971
Conservative Utilization

This provider writes prescriptions for this formulation 41.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222,240.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,346.72

State Avg Cost Per Claim

$13,202.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JUN ROSE ABELLA F.N.P. provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.